

Bruno Daniele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9632145/publications.pdf>

Version: 2024-02-01

16
papers

4,543
citations

1040056

9
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

4526
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2018, 19, 940-952.	10.7	1,816
2	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
3	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 282-296.	10.7	1,202
4	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.	3.7	55
5	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.	2.8	43
6	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	4.1	40
7	Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 2678-2695.	2.9	37
8	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated α -fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
9	Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> , 2021, 10, 2048.	4.1	20
10	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. <i>Biomedicines</i> , 2022, 10, 150.	3.2	11
11	How to Treat Hepatocellular Carcinoma in Elderly Patients. <i>Pharmaceuticals</i> , 2021, 14, 233.	3.8	9
12	Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , 2021, 38, 2472-2490.		9
13	Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. <i>Journal of Clinical Medicine</i> , 2021, 10, 1777.	2.4	8
14	From CENTRAL to SENTRAL (SERum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	3.7	7
15	The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7160.	4.1	4
16	Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. <i>Cancers</i> , 2012, 4, 549-565.	3.7	1